Research information only. PrecisePep is an educational library. It is not medical advice and is not intended to assist, encourage or enable self-administration. The compounds documented here are research chemicals — most are not approved for human use. Read the full disclaimer.
PrecisePep/Peptide Library/Oxytocin
Endocrine & Reproductive Axis
Pitocin® · Syntocinon® · carbetocin (analogue) · the "love hormone"
Nine residues, two clinical lives, and one of the widest gaps in medicine between what a molecule reliably does and what the internet says it does. It empties a uterus. Whether it changes how people feel about each other is a much harder question.
Two things are true about oxytocin at once, and most writing about it picks one and ignores the other.
The first: it is one of the most consequential drugs in obstetrics. It contracts uterine smooth muscle and causes milk ejection, and its use to induce or augment labour and to control postpartum haemorrhage has saved an enormous number of lives. Postpartum haemorrhage remains a leading cause of maternal death worldwide, and uterotonics are the front-line response. The World Health Organization keeps oxytocin — and its heat-stable analogue carbetocin — on the Essential Medicines List for exactly that reason.
The second: it is also the subject of a very large popular literature about trust, bonding, empathy and social connection, built on small early studies of intranasal administration that have replicated poorly. The largest and most rigorous trial of intranasal oxytocin in autistic children — 24 weeks, randomised, placebo-controlled — found no significant difference from placebo on social functioning.[1] Smaller studies have reported positive findings, some of them well conducted, but the pattern across the field is the familiar one: promising pilots, disappointing confirmatory trials.
There is also a basic pharmacological problem underneath the popular claims. Only a small fraction of intranasally administered oxytocin is thought to reach the brain, and the relationship between nasal dose and central concentration is poorly characterised. A great deal of the popular literature rests on assuming that relationship is favourable.
Oxytocin is a prescription medicine and this page publishes no unsupervised dosing for it. It is here because the conditions index names uterine atony among conditions treated by approved peptide drugs — and because unlike every other prescription peptide on this site, oxytocin does have a grey market, sold intranasally on social and sexual claims that its own trial record does not support.
Two separate hazards live on this page: the obstetric one, where the drug is powerful and requires monitoring, and the consumer one, where a nasal spray of uncertain content is sold against an evidence base that is far weaker than the marketing implies.
Uterine smooth muscle contraction. Oxytocin receptors are G-protein-coupled and raise intracellular calcium in myometrial cells. Receptor density increases dramatically through pregnancy and peaks at term, which is why the same dose produces almost nothing early in pregnancy and strong contractions at term. Sensitivity, not dose, is what changes.
Milk ejection. Contraction of myoepithelial cells around the mammary alveoli — the let-down reflex, which is a true neuroendocrine reflex triggered by suckling.
Central actions. Oxytocin is released within the brain as well as into the circulation, acting on amygdala, hypothalamic and striatal circuits involved in social salience and stress responses. The animal literature here is genuinely strong — prairie vole pair bonding is not a myth. Whether exogenous administration reproduces those effects in humans is the contested step.
Vasopressin cross-reactivity. Oxytocin and vasopressin differ at two of nine positions, and oxytocin has meaningful antidiuretic activity at higher doses. Prolonged infusion with large volumes of electrolyte-free fluid can cause water intoxication with seizures and coma — the mechanism that connects this page to desmopressin.
Why the nasal route is the weak link in the popular claims. Intranasal delivery is proposed to reach the brain partly via olfactory and trigeminal pathways. The fraction that arrives is small and variable, and plasma levels after nasal dosing do not predict central concentrations well. Much of the consumer market rests on treating this uncertainty as though it were resolved.
Effects that have been reported. A study-tier entry means a result was published — not that the effect is established, reproducible, or transferable from a rodent to a person.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
A first-line uterotonic for prevention and treatment of postpartum haemorrhage, and one of the interventions most responsible for reductions in maternal mortality. Carbetocin, a heat-stable analogue, extends this to settings without reliable cold chain.
Approved where there is a medical indication for delivery — not for convenience or scheduling. Used with continuous fetal and contraction monitoring because the therapeutic window is narrow.
The physiological basis of let-down, well characterised, and the reason nasal oxytocin was historically marketed to support breastfeeding — a use that has largely fallen away for lack of convincing evidence.
A 24-week randomised placebo-controlled trial of daily intranasal oxytocin in children and adolescents with autism spectrum disorder found no significant difference in social functioning. This is listed under study-reported because it is the strongest evidence available, and it is negative.
A large body of small crossover studies has reported effects on trust, emotion recognition and social attention. Effect sizes are modest, replication has been inconsistent, and publication bias in this literature has been examined and found substantial.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
One serious reading of the mixed data is that oxytocin increases the salience of social cues rather than producing warmth — which would predict increased in-group favouritism, envy and defensiveness in some contexts as readily as trust. This reframing fits the inconsistent results better than the "love hormone" account does.
Explored in early trials with results that have not consolidated into an approved use anywhere.
The dominant claim in the consumer nasal-spray market, resting on very small studies and on the physiological role of endogenous oxytocin release at orgasm. Endogenous release during an event is not evidence that exogenous administration enhances it.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
A substantial consumer market exists, largely through compounding pharmacies and grey-market suppliers. Reports are overwhelmingly positive and overwhelmingly uncontrolled — this is a compound whose claimed effects are exactly the kind most susceptible to expectancy.
A recurring theme in community reporting. Receptor desensitisation is one explanation; regression to the mean after an unusually good first experience is another.
The most commonly reported effects from intranasal use.
Oxytocin is unstable in solution and sensitive to temperature. A nasal spray of unknown concentration, unknown preservative and unknown storage history is a poor way to test a hypothesis about your own social life.
Adverse effects, contraindications and unknowns. The grey-market tier is where under-reporting is worst: uncontrolled use produces no systematic safety surveillance at all, so absence of a reported harm is not evidence of safety.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
The label states that available data are inadequate to evaluate the benefit-to-risk considerations, and that oxytocin is not indicated for elective induction — meaning induction in a pregnancy with no medical indication for delivery.
Excessive stimulation can compromise fetal oxygenation and, rarely, rupture the uterus. This is why oxytocin infusion requires continuous fetal heart rate and contraction monitoring and is titrated slowly.
The antidiuretic cross-activity, combined with large volumes of electrolyte-free fluid, can produce hyponatraemia severe enough to cause seizures, coma and death. A documented and preventable complication.
Hypotension, tachycardia and arrhythmia can follow rapid intravenous bolus administration, particularly at caesarean section — one reason slow administration or the carbetocin analogue is often preferred.
Neonatal jaundice, retinal haemorrhage and low Apgar scores have been associated with maternal oxytocin administration in labelled adverse event data.
Trials of intranasal oxytocin have not identified serious safety signals at the doses studied, which is a statement about tolerability rather than about efficacy.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
Trials run for weeks to months. Consumer use runs for years. Receptor regulation, and any effect on endogenous oxytocin signalling, over that horizon is simply unknown.
If the social salience account is right, heightened attention to social cues would be unwelcome in some people and in some situations. Reports of increased anxiety and social discomfort exist alongside the positive ones.
Oxytocin degrades in solution and is temperature-sensitive, which is precisely why the heat-stable analogue carbetocin was developed for low-resource settings. A compounded spray stored at room temperature for months is unlikely to contain what its label claims.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The most-reported effect of intranasal use.
Typical for any peptide nasal spray.
Reported in both directions — tearfulness and openness described as often as calm.
The single most consistent theme in long-term community reporting.
Figures below are documented, not recommended. Study ranges come from published protocols in the stated model; grey-market ranges are what the research community reports using and carry no safety validation of any kind.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Labour induction and augmentation use a dilute intravenous infusion titrated against uterine response with continuous fetal monitoring, and postpartum use has its own separate regimens. These are inpatient protocols requiring monitoring equipment, and no figures are reproduced here.
Trials have most often used doses in the tens of international units administered intranasally, with wide variation in protocol, device and timing between studies. That heterogeneity is one reason the literature has replicated so poorly.
| Question | Position |
|---|---|
| Approved for postpartum haemorrhage? | Yes — a first-line uterotonic |
| Approved for medically indicated induction? | Yes, with monitoring |
| Approved for elective induction? | No — boxed warning |
| Approved for autism, anxiety or bonding? | No — nowhere, in any jurisdiction |
| Largest autism trial result | No significant difference from placebo at 24 weeks |
| Intranasal brain delivery | Small, variable and poorly characterised |
| Grey market exists? | Yes — nasal sprays, on claims the trials do not support |
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
There is no validated relationship between an intranasal dose and a central concentration, which means there is no defensible way to select a dose for a social or psychological purpose.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Consumer sprays are typically sold at fixed metered doses, used before social or intimate situations. This site does not publish figures — not because the acute risk is high at studied doses, but because there is no established dose-response for the effect being sought, which makes any number an invention.
Occasionally described in community discussion. Injectable formulations are not designed, preserved or concentrated for nasal use, and this is a poor idea for reasons of sterility as much as pharmacology.
Combination effects. Almost no peptide combination has been studied as a combination in humans; stack logic is overwhelmingly mechanistic inference and community practice. Each linked compound has its own page.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Sequential use with ergometrine, misoprostol or carboprost is standard practice where oxytocin alone does not achieve uterine tone. Guideline-driven and well established.
The WOMAN trial supported tranexamic acid in postpartum haemorrhage; the two act on different arms of the problem — uterine tone and fibrinolysis.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The one study design that has produced repeatedly encouraging results in autism paired oxytocin with structured positive social interaction rather than giving it alone. That is a meaningful signal about where any effect might sit — as a possible facilitator of learning, not as a treatment.
PT-141 is approved for hypoactive sexual desire disorder in premenopausal women on randomised trial evidence, acting through melanocortin receptors. Oxytocin has no such approval or evidence base for that use.
Oxytocin has antidiuretic cross-activity. Combining it with a V2 agonist would compound hyponatraemia risk.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
Combined with Selank and similar compounds in community protocols for social settings. No study has examined any such combination.
Whole schedules — dosing, titration, cycle length, and off-time — as documented in trials, as proposed from mechanism, and as circulated in the research community. Reproduced for study and comparison only.
Highest confidenceReported in peer-reviewed literature, registered clinical trials, or regulatory filings. Note the model: much peptide literature is in vitro or rodent work, not human trial data.
Prophylactic uterotonic administration after delivery, with controlled cord traction and uterine massage, reduces postpartum haemorrhage. One of the most consequential protocols in obstetric practice.
Dilute infusion, incremental titration, continuous fetal heart rate and contraction monitoring, with defined criteria for reducing or stopping.
Randomised, placebo-controlled, daily intranasal administration with a validated social withdrawal endpoint. The design was sound; the result was negative.
Unproven — inference onlyExtrapolated from a known mechanism, receptor profile, or adjacent compound class. Biologically plausible but not directly demonstrated for this compound in this context.
The design used in the pilot work that reported benefit — infrequent dosing followed immediately by positive social interaction — is the more interesting hypothesis, and it has not been confirmed at scale.
Uncontrolled reportsAggregated from research-community logs, forums, vendor literature and self-reported experience. Uncontrolled, unverified, subject to placebo, polypharmacy and product-purity confounds. Lowest evidentiary weight.
The dominant community pattern. Expectancy effects in this setting are large enough that self-assessment is close to uninformative.
The obstetric indications are covered above. This section is about the other oxytocin — the intranasal consumer market built on trust, bonding and intimacy claims — because unlike every other prescription drug in this library, that market is real and substantial.
No psychiatric, social, bonding or sexual indication is approved for oxytocin anywhere. Intranasal oxytocin sold for those purposes is unapproved use of a prescription hormone, generally through compounding or grey-market supply, against a trial record whose most rigorous result was negative.
Pathophysiology
Autism involves differences in social communication and interaction. There is no pharmacological treatment for the core features, which is why a candidate attracts attention.
Mechanistic rationale
A randomised, placebo-controlled trial of daily intranasal oxytocin in children and adolescents with autism spectrum disorder over 24 weeks found no significant difference from placebo on social functioning. Smaller pilot studies have reported benefit, some well conducted — notably designs pairing infrequent dosing with structured positive social interaction, which is a more interesting hypothesis and remains unconfirmed at scale. The overall pattern is the familiar one: promising pilots, disappointing confirmatory trials.
Community reports
The negative result is rarely cited by sellers. The pilot results are.
Components carrying the argument: Central oxytocin signalling
Pathophysiology
Oxytocin is released within the brain and acts on amygdala, hypothalamic and striatal circuits involved in social salience and stress responses. The animal literature is genuinely strong.
Mechanistic rationale
A large body of small human crossover studies reported effects on trust, emotion recognition and social attention. Effect sizes are modest, replication inconsistent, and publication bias in this literature has been examined and found substantial. A serious alternative reading is that oxytocin increases the salience of social cues rather than producing warmth — which would predict increased in-group favouritism, envy and defensiveness in some contexts as readily as trust, and fits the inconsistent results better than the "love hormone" account does.
Community reports
Reported effects fade with repeated use — the most consistent theme in long-term community reporting. Receptor desensitisation is one explanation; regression to the mean after an unusually good first experience is another.
Components carrying the argument: Central social salience circuits
Pathophysiology
Intranasal delivery is proposed to reach the brain partly via olfactory and trigeminal pathways.
Mechanistic rationale
Only a small and variable fraction of an intranasal dose is thought to reach the brain, and plasma levels after nasal dosing predict central concentrations poorly. Much of the popular literature treats that uncertainty as resolved. Oxytocin is also unstable in solution and heat-sensitive — which is precisely why the heat-stable analogue carbetocin was developed for low-resource obstetric settings — so a compounded spray stored at room temperature for months is a poor instrument for testing a hypothesis about your own social life.
Community reports
Diminishing effect over time is commonly reported and is at least as consistent with product degradation as with tolerance.
Components carrying the argument: Nasal-to-brain delivery, poorly characterised
Pathophysiology
Endogenous oxytocin is released at orgasm, which is the physiological observation the claim rests on.
Mechanistic rationale
Endogenous release during an event is not evidence that exogenous administration enhances it. Very small studies exist. PT-141 is the compound in this space with randomised evidence and an approval, acting through melanocortin receptors rather than the oxytocin system, and the two are frequently discussed as equivalents when they are not comparable on evidence.
Community reports
The main driver of the consumer nasal spray market.
Components carrying the argument: Inferred from endogenous physiology
| Question | Position |
|---|---|
| Approved for social/sexual use anywhere? | No |
| Largest autism trial | No difference from placebo at 24 weeks |
| Social cognition literature | Modest effects, poor replication, publication bias |
| Alternative reading | Increases social salience — not necessarily warmth |
| Intranasal brain delivery | Small, variable, poorly characterised |
| Product stability | Degrades with heat and time — hence carbetocin |
| Obstetric boxed warning | Not indicated for elective induction of labour |
For postpartum haemorrhage: active management of the third stage, sequential uterotonics, tranexamic acid, tamponade, and surgical or radiological intervention where needed. For autism: no pharmacological treatment addresses the core features; evidence-based support focuses on communication, education and individualised services, with medication reserved for co-occurring conditions. For low sexual desire: relationship and psychological factors, medication review — SSRIs especially — and sex therapy, which has an evidence base and is under-used.
Physical-chemistry reference for laboratory handling of the lyophilised material. Reproduced so that stability and concentration mathematics can be studied — see the calculator for the arithmetic and the reconstitution guide for sterile technique.
The licensed injectable is a ready-to-use solution diluted into intravenous fluid by clinical staff; nasal formulations are compounded or manufactured as metered sprays. This site publishes no reconstitution or dilution arithmetic for oxytocin.
Refrigerated storage is specified for many oxytocin injection products, with limited room-temperature periods — oxytocin degrades in solution and is heat-sensitive. Carbetocin was developed specifically because that instability makes oxytocin unreliable without a cold chain.
Injectable: 10 IU/mL ampoules and vials. Nasal sprays are supplied as metered-dose devices at varying concentrations.
Heat and time are the enemies. A compounded nasal spray stored at room temperature for months is a plausible candidate for having lost much of its content, which is one reason community reports of diminishing effect are hard to interpret.
Regulatory status changes and differs by country. This is a summary for orientation, not legal advice — check your own jurisdiction.
Approved prescription medicine. Licensed as Pitocin, Syntocinon and generics for medically indicated induction and augmentation of labour and for control of postpartum bleeding. On the WHO Essential Medicines List, alongside the heat-stable analogue carbetocin.
Boxed warning: oxytocin is not indicated for elective induction of labour, on the basis that the available data are inadequate to evaluate the benefit-to-risk balance for that use.
No psychiatric, social, bonding or sexual indication is approved anywhere. Intranasal oxytocin sold for those purposes is unapproved use of a prescription hormone, generally through compounding or grey-market supply, against a trial record whose most rigorous result was negative.
Regulatory and trial claims re-checked against primary sources on 16 August 2026. Checked: elective induction boxed warning; intranasal autism trial result. Approvals, trial readouts and compounding decisions move faster than anything else on this page — a date here means someone looked, not that nothing has changed since.
Not a performance compound and not specifically named on the WADA Prohibited List, but peptide hormones as a class are addressed there. Verify against the current list.
Links resolve to PubMed records, trial registries, publisher pages or primary documents. Where a body of work rather than a single paper is cited, the link opens a PubMed query so the full result set — including newer papers than this page — can be reviewed. Verify every claim against the primary source before relying on it.
For educational and research reference only. Nothing on this site is medical advice, a recommendation, or an instruction to administer any substance to a human being. Every figure on this page is a record of what has been reported, not a recommendation. Full disclaimer.
